Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

5 Low-Cost Top-Ranked ETFs To Tap At Discounted Prices

Published 03/20/2020, 08:00 AM
Updated 07/09/2023, 06:31 AM

Stocks have been experiencing a turbulent phase of late due to the coronavirus’ heavy blow on the economy and the oil price war. Amid this, some analysts believe that markets have hit a bottom and might turn around while some predict more pain ahead (read: Do Low Volatility ETFs Outperform During Market Turmoil?).

Meanwhile, global central banks and governments have been coming up with a series of massive stimulus to alleviate the effect of the virus. The Fed cut rates to zero and restarted QE measures. Meanwhile, the Trump administration is negotiating a massive $850-billion stimulus package with Congress (read: U.S. Dollar Climbs: ETFs to Gain/Lose).

Japan’s Prime Minister Shinzo Abe plans to launch massive pandemic stimulus. Also, there is likelihood of buying of exchange-traded funds by the Bank of Japan and public pension funds. The ECB has also announced a new, expanded program to buy up to 750 billion euros ($820 billion) in government and private sector bonds as well as commercial paper by year-end. Many other central banks are cutting rates to record low levels and announcing pandemic package (read: ETFs to Gain on ECB's Coronavirus Emergency Stimulus Rollout).

Investors should note that the Dow Jones, the S&P 500 and the Nasdaq Composite lost at least 25% from their all-times highs achieved in mid-February, ensuring a bear market. While looking at the corporate earnings strength, the S&P 500 companies’ earnings are expected to decline 1.7% in the first quarter of 2020, per Earnings Trends issued on Mar 17, 2020. Technology and Medical sectors are expected to log 5.1% and 3.4% growth, respectively.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The estimates do not appear that bad given the severity of the pandemic. But the question is whether analysts were able to take the exact impact of the pandemic into account. Only the release of Q1 earnings results will tell.

Still, markets can’t stay at this level for long. No one really knows when the coronavirus-induced market turmoil will ease but the rollout of gigantic global stimulus signals light at the end of the tunnel (read: Has Wall Street's March Madness Peaked? ETFs to Tap).

ETFs Available for Cheap

Against this backdrop, we highlight a few ETFs that lost heavily in the latest Wall Street carnage. These ETFs have a Zacks Rank #1 (Strong Buy) or 2 (Buy), very cheap expense ratios in the respective spaces and one-month loss of at least 30%

These ETFs are likely to turn around once the virus contagion is contained, consumer confidence improves and investors’ sentiments rise.

Schwab U.S. Large-Cap Value ETF SCHV

Zacks ETF Rank: #2
Expense Ratio: 0.04%
One-Month Loss: Down 30.7%

Fidelity MSCI Information Technology Index ETF (TSXV:FTEC)

Zacks ETF Rank: #1
Expense Ratio: 0.08%
One-Month Loss: Down 30.0%

Materials Select Sector SPDR Fund XLB

Zacks ETF Rank: #2
Expense Ratio: 0.13%
One-Month Loss: Down 31.6%

SPDR S&P Internet ETF XWEB

Zacks ETF Rank: #2
Expense Ratio: 0.35%
One-Month Loss: Down 36.7%

SPDR S&P Biotech (NYSE:XBI) ETF XBI

Zacks ETF Rank: #2
Expense Ratio: 0.35%
One-Month Loss: Down 32.1%

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Materials Select Sector SPDR ETF (XLB): ETF Research Reports

SPDR S&P Biotech ETF (XBI): ETF Research Reports

Fidelity MSCI Information Technology Index ETF (FTEC): ETF Research Reports

SPDR S&P Internet ETF (XWEB): ETF Research Reports

Schwab U.S. Large-Cap Value ETF (SCHV): ETF Research Reports

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.